0000014272-18-000059.txt : 20180221 0000014272-18-000059.hdr.sgml : 20180221 20180221201433 ACCESSION NUMBER: 0000014272-18-000059 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180215 FILED AS OF DATE: 20180221 DATE AS OF CHANGE: 20180221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Santiago Karen Murphy CENTRAL INDEX KEY: 0001732137 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 18630309 MAIL ADDRESS: STREET 1: BRISTOL-MYERS SQUIBB COMPANY STREET 2: RT. 206 & PROVINCE LINE ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 3 1 wf-form3_151926205920363.xml FORM 3 X0206 3 2018-02-15 0 0000014272 BRISTOL MYERS SQUIBB CO BMY 0001732137 Santiago Karen Murphy BRISTOL-MYERS SQUIBB COMPANY 345 PARK AVENUE NEW YORK NY 10154 0 1 0 0 Controller Common Stock, $0.10 par value 403 D Market Share Units 2018-03-10 Common Stock, $0.10 par value 333.0 D Market Share Units 2019-03-10 Common Stock, $0.10 par value 551.0 D Market Share Units 2020-03-10 Common Stock, $0.10 par value 1062.0 D Market Share Units 2021-03-10 Common Stock, $0.10 par value 1641.0 D Performance Shares 2018-03-10 Common Stock, $0.10 par value 2760.4 D Performance Shares 2019-03-10 Common Stock, $0.10 par value 2123.0 D Performance Shares 2020-03-10 Common Stock, $0.10 par value 2461.0 D Restricted Stock Units 2020-09-01 Common Stock, $0.10 par value 1924.0 D These market share units will vest on March 10, 2018. Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. One-half of these market share units will vest on each of March 10, 2018 and March 10, 2019. One-third of these market share units will vest on each of March 10, 2018, March 10, 2019, and March 10, 2020. Twenty-five percent of these market share units will vest on each of the first, second, third, and fourth anniversaries of the grant date, starting on March 10, 2018. Each performance share converts into one share of common stock upon distribution in the first quarter of 2018, subject to a Total Shareholder Return modifier. Each performance share converts into one share of common stock upon distribution in the first quarter of 2019. Each performance share converts into one share of common stock upon distribution in the first quarter of 2020. The restricted stock units vest in three equal annual installments beginning on September 1, 2018. Each restricted stock unit converts into one share of common stock upon vesting. EXHIBIT LIST: EX-24 Exhibit 24 - Karen M. Santiago Power of Attorney /s/ Lisa A. Atkins, attorney-in-fact for Karen M. Santiago 2018-02-21 EX-24 2 corresp.htm EXHIBIT 24 - KAREN M. SANTIAGO POWER OF ATTORNEY

POWER OF ATTORNEY




    I, Karen M. Santiago, Corporate Controller of Bristol-Myers Squibb Company (the
"Company"),  a corporation duly organized and existing under the laws of the State of Delaware,
 in the United States of America, and having its principal place of business at 345 Park Avenue,
New York, New York, do hereby constitute and appoint each of Sandra Leung, Katherine R.
Kelly, Yun Jung Choi and Lisa A. Atkins, individually, as my lawful attorney-in-fact and in my
 name, place and stead to execute and deliver any and all documents relating to insider reporting
 requirements under Section 16 of the Securities Exchange Act of 1934 with respect to securities
 issued by the Company, including, without limitation, the execution and filing of all Forms 3, 4
 and 5, and to take such other action, as such attorney considers necessary or appropriate, to
 effectuate such transactions.  This Power of Attorney shall remain in full force and effect until I
 am no longer required to file Forms 3, 4, and 5 with respect to securities issued by the Company,
 unless earlier revoked.


    IN WITNESS WHEREOF, I have executed this Power of Attorney on this 13 day of February, 2018.



    /s/ Karen M. Santiago
                              Karen M. Santiago